SIRT1 contributes to neuroendocrine differentiation of prostate cancer

被引:24
|
作者
Ruan, Lin [1 ,2 ]
Wang, Lei [3 ]
Wang, Xiaosong [1 ,4 ]
He, Ming [1 ,4 ]
Yao, Xiaoguang [1 ,4 ]
机构
[1] Hebei Univ Chinese Med, Hebei Key Lab Integrat Med Liver Kidney Patterns, Shijiazhuang, Hebei, Peoples R China
[2] Hebei Med Univ, Dept Nephrol, Hosp 1, Shijiazhuang, Hebei, Peoples R China
[3] Hebei Med Univ, Dept Urol, Hosp 1, Shijiazhuang, Hebei, Peoples R China
[4] Hebei Univ Chinese Med, Coll Integrat Med, Shijiazhuang, Hebei, Peoples R China
关键词
prostate cancer; SIRT1; neuroendocrine; N-Myc; Akt; OXIDATIVE STRESS; CELL-SURVIVAL; RESISTANT; EXPRESSION; P53; PROMOTES; MODULATION; APOPTOSIS; AUTOPHAGY; GENOMICS;
D O I
10.18632/oncotarget.23111
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The epigenetic factor SIRT1 can promote prostate cancer progression, but it is unclear whether SIRT1 contributes to neuroendocrine differentiation. In this study, we showed that androgen deprivation can induce reactive oxygen species production and that reactive oxygen species, in turn, activate SIRT1 expression. The increased SIRT1 expression induces neuroendocrine differentiation of prostate cancer cells by activating the Akt pathway. In addition, the interaction between Akt and SIRT1 is independent of N-Myc and can drive the development of neuroendocrine prostate cancer when N-Myc is blocked. Furthermore, SIRT1 facilitates tumor maintenance, and targeting SIRT1 may reduce the tumor burden during androgen deprivation. Our findings suggest that SIRT1 is a potential target for therapeutic intervention.
引用
下载
收藏
页码:2002 / 2016
页数:15
相关论文
共 50 条
  • [21] SIRT1 contributes in part to cisplatin resistance in cancer cells by altering mitochondrial metabolism
    Liang, Xing-Jie
    Finkel, Toren
    Shen, Ding-Wu
    Yin, Jun-Jie
    Aszalos, Adorjan
    Gottesman, Michael M.
    MOLECULAR CANCER RESEARCH, 2008, 6 (09) : 1499 - 1506
  • [22] Active regulator of SIRT1 is required for cancer cell survival but not for SIRT1 activity
    Knight, John R. P.
    Allison, Simon J.
    Milner, Jo
    OPEN BIOLOGY, 2013, 3 (11)
  • [23] Neuroendocrine differentiation in the progression of prostate cancer
    Komiya, Akira
    Watanabe, Akihiko
    Yasuda, Kenji
    Ichimatsu, Keisuke
    Fuse, Hideki
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2010, 26 : S37 - S37
  • [24] Neuroendocrine differentiation in the progression of prostate cancer
    Komiya, Akira
    Suzuki, Hiroyoshi
    Imamoto, Takashi
    Kamiya, Naoto
    Nihei, Naoki
    Naya, Yukio
    Ichikawa, Tomohiko
    Fuse, Hideki
    INTERNATIONAL JOURNAL OF UROLOGY, 2009, 16 (01) : 37 - 44
  • [25] Neuroendocrine differentiation in prostate cancer - a review
    Popescu, R.
    Bratu, Ovidiu
    Spinu, D.
    Marcu, D.
    Farcas, C.
    Dinu, Marius
    Mischianu, Dan
    ROMANIAN JOURNAL OF MILITARY MEDICINE, 2015, 118 (03) : 16 - 19
  • [26] Neuroendocrine differentiation in prostate cancer and development
    Sanders, Danielle N.
    Grabowska, Magdalena
    Matusik, Robert
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2016, 25 (03)
  • [27] The spectrum of neuroendocrine differentiation in prostate cancer
    Siyuan Cheng
    Xiuping Yu
    Prostate Cancer and Prostatic Diseases, 2021, 24 : 1214 - 1215
  • [28] The spectrum of neuroendocrine differentiation in prostate cancer
    Cheng, Siyuan
    Yu, Xiuping
    PROSTATE CANCER AND PROSTATIC DISEASES, 2021, 24 (04) : 1214 - 1215
  • [29] Neuroendocrine differentiation in the precursors of prostate cancer
    diSantAgnese, PA
    EUROPEAN UROLOGY, 1996, 30 (02) : 185 - 190
  • [30] Neuroendocrine differentiation of prostate cancer: a review
    Parimi, Vamsi
    Goyal, Rajen
    Poropatich, Kate
    Yang, Ximing J.
    AMERICAN JOURNAL OF CLINICAL AND EXPERIMENTAL UROLOGY, 2014, 2 (04): : 273 - 285